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MITOCHONDRIAL COMPLEX III RIESKE Fe-S PROTEIN PROCESSING AND ASSEMBLY 
Erika Fernandez-Vizarra and Massimo Zeviani 
MRC-Mitochondrial Biology Unit, University of Cambridge, Hills Road, CB2 0XY, 
Cambridge, UK. 
ABSTRACT 
Regulation of the mitochondrial respiratory chain biogenesis is a matter of great interest 
because of its implications for mitochondrial disease. One of the mitochondrial disease 
genes recently discovered associated to encephalopathy and mitochondrial complex III 
(cIII) deficiency is TTC19. Our study of TTC19-deficient human and mouse models, has 
led us to propose a post-assembly quality control role or ‘husbandry’ function for this 
factor that is linked to Rieske Fe-S protein (UQCRFS1). UQCRFS1 is the last incorporated 
cIII subunit, and its presence is essential for enzymatic activity. During UQCRFS1 
assembly, the precursor is cleaved and its N-terminal part remains bound to the 
complex, between the two core subunits (UQCRC1 and UQCRC2). In the absence of 
TTC19 there is a prominent accumulation of these UQCRFS1-derived N-terminal 
fragments that proved to be detrimental for cIII function. In this article we will discuss 
some ideas around the UQCRFS1 processing and assembly and its importance for the 
regulation of cIII activity and biogenesis.  
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COMPLEX III OVERVIEW 
The mitochondrial respiratory chain (MRC) is composed of four multimeric enzymes, 
responsible for the redox reactions that take electrons from NADH and FADH2, 
ultimately reducing molecular oxygen to water. This electron transfer is coupled to 
proton pumping from the matrix to the intermembrane space, generating a proton 
electrochemical gradient, which is the driving force for the condensation of ADP+Pi by 
the FO-F1 ATP synthase, a fifth complex, which together with complexes I to IV form the 
oxidative phosphorylation system (OXPHOS).  
Complex III (cIII) or ubiquinol:cytochrome c oxidoreductase is the center of the MRC, 
transferring electrons from coenzyme Q  (CoQ or just Q) to cytochrome c.  
X-ray diffraction crystal structures of cIII are available from Bos taurus 1, Gallus gallus 2, 3 
and Saccharomyces cerevisiae 4 as well as a cryo-EM structure that has recently been 
published from Homo sapiens 5. All of them are practically identical in shape and subunit 
composition. In all of these organisms, cIII is a tightly bound symmetrical dimer where 
one mitochondrial DNA (mtDNA) and nine nuclear genes encode the structural subunits 
forming each cIII monomer. Of all these subunits, only three possess electron transfer 
properties: 1) the mtDNA-encoded cytochrome b (MT-CYB in the mammalian 
nomenclature) that contains the two Q binding sites (Qo or QP and Qi or QN) and two b-
type hemes with different redox potentials (bL and bH): 2) cytochrome c1 (CYC1) that 
contains one c-type heme and 3) the Rieske Fe-S protein (UQCRFS1), whose 
intermembrane space-facing hydrophilic C-terminus hosts a 2Fe-2S high-potential 
cluster.  
The electron transfer and proton pumping processes within cIII occur according to a ‘Q-
cycle’ model 6, 7. UQCRFS1 receives one of the two electrons from oxidation of one 
ubiquinol molecule, and transfers it to CYC1. During this redox reaction, UQCRFS1 ‘head’ 
moves, towards the CYC1 subunit of one of the monomers, whereas the N-terminal 
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transmembrane domain is in close contact with MT-CYB of the other monomer 8. The 
reason for this configuration may be to provide stability to the dimeric cIII2 structure.  
 
MAMMALIAN COMPLEX III ASSEMBLY PROCESS 
Most of what is known about the assembly of cIII comes from studies in yeast 9, 10.  Based 
on the structural similarities and the fact that the first and last steps of human cIII 
assembly are conserved, it is assumed that the in-between process will be the same in 
yeast and mammals 11.  
CIII assembly starts with the synthesis of cytochrome b by dedicated ribosomes, where 
the yeast translation factors Cbp3 (mammalian UQCC1) and Cbp6 (UQCC2) are bound to 
the peptide exit tunnel and direct the nascent polypeptide to translocate into the 
mitochondrial inner membrane 12, 13. A third factor, Cbp4 (UQCC3), is bound to 
cytochrome b after the bL heme but before the bH heme are incorporated into the 
apoprotein 14. Pathological mutations associated with human cIII deficiency have been 
described in UQCC2 15 and UQCC3 16. These early assembly factors are released when the 
first nuclear-encoded subunits bind to cytochrome b. Cbp3 and Cbp6 are now liberated 
and can bind to the mitochondrial ribosomes to act again as translational activators for 
cytochrome b. The rest of the structural subunits are then incorporated into the nascent 
complex until only Rip1 (UQCRFS1) and the smallest subunit Qcr10 (UQCR11) are 
missing, in an already dimeric structure named as pre-cIII2 10, 11. The incorporation of 
Rip1/UQCRFS1 can be considered as the crucial cIII2 maturation step because it is then 
that the enzyme becomes catalytically active. As depicted in Figure 1, UQCRFS1 is 
synthesized as a precursor protein in the cytosol and imported to the mitochondrial 
matrix following the TOM and TIM23 pathway, similarly to other proteins containing 
cleavable mitochondrial targeting sequences (MTS) 17. In the matrix, UQCRFS1 binds to 
MZM1L/LYRM7 18-20, the LYR-motif containing chaperone responsible for its 
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stabilization and for the recruitment of the Fe-S transfer complex in the matrix 21, 22. 
Once UQCRFS1 has acquired its 2Fe-2S cluster, BCS1L translocates and incorporates it 
to pre-cIII2 in the IM 23-25. This function is therefore essential for cIII2 activity and 
mutations in BCS1L are the most frequent cause of mitochondrial disease associated to 
cIII deficiency (reviewed in ref. (11)). Pathological mutations have also been described 
in LYRM7 26-29} and in TTC19, encoding a third factor necessary for UQCRFS1 metabolism 
30, 31, which is not present in yeast and will be discussed in more detail below.  
 
BOVINE CIII SUBUNIT 9: THE UQCRFS1 MITOCHONDRIAL TARGETING SEQUENCE 
One interesting observation that was pointed out as the main difference between the 
bovine cIII and the yeast and chicken enzymes was that the bovine complex contained 
eleven subunits instead of the ten found in the latter organisms. This extra subunit with 
a molecular mass of 8 kDa was called ‘subunit 9’ or SU9 32, 33 and its sequence was 
determined to be the 78 N-terminal amino acids of the UQCRFS1 precursor, i.e. its MTS 
34.  As a norm, proteins directed to the mitochondrial matrix contain an N-terminal 
amphipathic helix of variable length, which is recognized by the TOM complex and 
directs the precursor protein to the TIM23 complex to be translocated to the 
mitochondrial matrix. Here the precursor is then processed by the matrix processing 
peptidase (MPP), which cleaves off the MTS and gives rise to the mature protein 35. 
Normally, the MTS peptides are proteolysed by Cym1/PITRM1 or hPreP, as their 
accumulation inside mitochondria could have a highly toxic effect 36. Therefore, the 
presence of the UQCRFS1 MTS incorporated inside cIII as a structural subunit 
represents an anomaly and the reason why this happens is unknown.  
Yeast Rip1 has a much shorter MTS than mammalian and avian UQCRFS1: 30 amino 
acids vs. 78 and 76, respectively (Figure 2). Interestingly, TTC19 orthologs exist in 
organisms with long UQCRFS1 MTS, while absent in yeast. The processing of yeast Rip1 
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is also different from bovine UQCRFS1. Rip1 is processed in two steps, first 22 N-
terminal amino acids are cleaved by the MPP, generating an intermediate form of Rip1 
(iRip1), and, in a second step, the mitochondrial intermediate peptidase (MIP) removes 
the next octapeptide to give rise to the mature form of the Rieske Fe-S protein (mRip1) 
37. This processing was proposed to happen once Rip1 is inserted into cIII2 38. In the case 
of the bovine enzyme, a single-step processing of UQCRFS1 seems to be carried out by 
MPP after it is incorporated into cIII2 34, where SU9 remains bound to the complex and 
localized between the two core subunits (UQCRC1 and UQCRC2), as determined in the 
crystal structure (Figure 3) 1. When chicken cIII2 was isolated and crystallized for the 
first time, no SU9 was identified 2, leading to the idea that there was no such UQCRFS1-
derived subunit in the avian enzyme.  
UQCRC1 and UQCRC2 are homologous to the two MPP subunits (MPP and MPP, 
respectively), and in plants they still preserve their processing properties 39. Mammalian 
cIII2 was considered to have lost its MPP activity. However, when the isolated enzyme 
was treated with detergents it showed this activity 40. The same phenomenon was 
observed by reconstitution of the system with recombinant UQCRC1 and UQCRC2; 
interestingly, MPP activity was inhibited when stoichiometric amounts of ‘SU9’ were 
formed by adding N-terminal UQCRFS1 peptides as substrate 41. 
Taking all this information together, it is plausible that UQCRFS1 is processed in situ by 
UQCRC1+UQCRC2 MPP activity when incorporated into pre-cIII2 (Figure 1). This would 
explain why the N-terminus of the UQCRFS1 precursor is found between these two 
subunits in the cIII2 structure and inhibits its MPP activity. This mode of action was also 
postulated based on the structural features of vertebrate cIII2 42. 
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N-TERMINAL UQCRFS1 PEPTIDES BOUND TO MAMMALIAN AND AVIAN CIII2  
After the identification of the first pathological mutations in TTC19 30 our laboratory got 
interested in determining the molecular function of this factor, related with cIII2 
biogenesis. For that reason we have studied TTC19-deficient cells and a knock out 
(Ttc19-/-) mouse model, whose characterization was recently published 31. In this report, 
by importing radioactively labeled UQCRFS1 in isolated mouse liver mitochondria and 
analyzing its incorporation into cIII2 in a time course, we found that UQCRFS1 is 
processed right after its import and assembly, and the peptides derived from the N-
terminus of the UQCRFS1 precursor remain bound to the complex. However, we did not 
find evidence of a unique cleavage point, giving rise to only two fragments 
corresponding to the mature UQCRFS1 and the 78-amino acid long SU9. Contrariwise, 
we observed the formation of the mature UQCRFS1 and the appearance of three main 
species of approximately 4, 8 and 12 kDa in size. In the steady state, these small 
UQCRFS1-derived peptides were readily detectable in the Ttc19-/- tissues while they 
were practically absent in the Ttc19wt samples. By mass spectrometry we were able to 
find tryptic peptides spanning from positions 8 to 204 of the UQCRFS1 precursor in the 
lower part of a SDS-PAGE (corresponding to sizes of 14 kDa and smaller), whereas in the 
higher part of the gel (30-14 kDa) we could only find peptides within the sequence of 
the mature protein (from residues 84 to 274) 31.  
When checking the twenty-two bovine and sixteen chicken cIII2 crystal structures 
available in the RCSB PDB protein data bank (https://www.rcsb.org) 43 there are 
peptides derived from UQCRFS1 MTS in all of them (examples in Figure 3).  In the 
original chicken structure, density corresponding to an amino acid chain sitting between 
UQCRC1 and UQCRC2 was detected and a chain was built in the structure, but the 
identity of this peptide remained unknown (PBD ID 1BCC, 2BCC, 3BCC) 3. This issue was 
resolved in the later chicken structures (see Table 1). Even though all the structures 
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contain these peptides, the sequences in each of one of them are very variable and in 
none of them the full UQCRFS1 MTS, from amino acids 1 to 78, is found (Table 1). This 
could reflect heterogeneity in the fragments that are contained in each of the analyzed 
cIII2 crystals 42.  
In our in organello assays, after import and incorporation into cIII2 of radioactive mouse 
Uqcrfs1, we observed that the 8 and 12 kDa fragments that are generated immediately 
after incorporation, disappeared with time and this clearance was much more efficient 
in wild-type compared to Ttc19-/- mitochondria. The abnormal accumulation of the N-
terminal peptides was associated with aberrant electrophoretic mobility of cIII2 in Blue-
Native gel electrophoresis (BNGE), defective enzymatic activity and increased reactive 
oxygen species (ROS) production. Therefore, we concluded that during the 
incorporation and in situ UQCRFS1 processing, several peptides containing its MTS are 
produced and remain bound to cIII2. However, in order to preserve cIII2 structural 
integrity and function, these peptides (at least those of 8 kDa and 12 kDa) must be 
removed. TTC19 is involved in the removal of these N-terminal UQCRFS1 peptides, as 
discussed in the next section.  
 
ROLE OF TTC19 IN COMPLEX III BIOGENESIS AND FUNCTION 
Since the first TTC19 mutations were published in 2011 30, a significant number of cases 
have been subsequently reported 44, 45. The biochemical profile of these patients, 
showing isolated cIII deficiency, underscores the importance of TTC19 for a correct 
biogenesis of this complex. Analysis of cIII2 assembly state in TTC19-deficient skin 
fibroblasts and muscle biopsies revealed the presence of UQCRC1 and UQCRC2-
containing subassemblies 30, 31, which suggested an involvement of TTC19 in the first 
steps of cIII2 assembly. However, the availability of the Ttc19-/- mice and more detailed 
kinetic analyses in human cells, revealed that the assembly process per se was not 
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particularly altered in the absence of TTC19, including a normal incorporation of 
UQCRFS1 31. TTC19 is loosely bound to fully assembled cIII2, as this interaction is 
disrupted when treating the mitochondrial membranes with a relatively mild detergent 
such as n-Dodecyl--D-maltoside (DDM), but not if the samples are exposed to the even 
milder detergent Digitonin.  Moreover, TTC19 only binds to cIII2 if UQCRFS1 is 
incorporated into the complex 31, suggesting a role in cIII2 biogenesis or maturation after 
assembly is completed. In fact, because the absence of TTC19 impairs the removal of the 
small UQCRFS1-derived fragments, we assigned a quality control or “husbandry” role 
for TTC19, in maintaining the structural and functional integrity of cIII2.  
 
PROSPECTS  
The imminent questions derived from our recently published work 31 are: 1) whether 
UQCRC1+UQCRC2 possess MPP activity in vivo and what is their role in UQCRFS1 
processing, 2) what proteases are working in collaboration with TTC19 in the removal 
of UQCRFS1 N-terminal peptides produced during assembly-processing and 3) how this 
process intervenes in UQCRFS1 turnover, to warrant cIII2 fitness.  
As for the first question, in plants, MPP is integrated into cIII2, thus carrying out the 
processing of the precursor proteins in addition to act as an MRC complex 39. However, 
in S. cerevisiae and in mammals, there is a soluble MPP localized in the matrix. Only two 
reports cited above 40, 41, have demonstrated an MPP activity incorporated into purified 
bovine cIII2 and performed by UQCRC1+UQCRC2. It would be necessary to demonstrate 
in vivo whether this activity is necessary for the in situ processing and proper 
incorporation of UQCRFS1.  
Concerning the second question, we performed co-immunoprecipitation studies that 
revealed specific interactions of TTC19 with cIII2, in the context of the respiratory 
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supercomplexes (i.e. cI+cIII+cIV) 46 and with the components of the so-called SPY 
complex 47. This is a mitochondrial quality control “proteolytic hub” that includes both 
the i-AAA protease YME1L and the rhomboid protease PARL. Logically the SPY complex 
is the first candidate to be explored in relation to its role in UQCRFS1/cIII2 quality 
control.  
Regarding the third question and taking together the information reported above, this 
process can be considered as a regulatory mechanism of cIII2 maturation and activity. 
Even in situations in which UQCRFS1 cannot be incorporated, there is an assembly of 
pre-cIII2, which contains all the subunits except UQCRFS1 and most probably the 
smallest UQCR11 20, 25. Therefore, the pre-cIII2 can be considered as an assembly 
checkpoint previous to the final activation, which must be somehow regulated. 
Accordingly, UQCRC1+UQCRC2 could control the amount of UQCRFS1 that must be 
incorporated into cIII2 by recognizing the UQCRFS1 MTS and processing it upon 
incorporation. The presence of the N-terminal UQCRFS1 fragments in between UQCRC1 
and UQCRC2 would inhibit their MPP activity and the incorporation of any new 
UQCRFS1. The removal of the UQCRFS1 N-terminal fragments would reactivate cIII2 
MPP activity and promote the removal of old, possibly damaged, UQCRFS1 from the pre-
cIII2 scaffold, so that new UQCRFS1 can then be processed and incorporated again. This 
would keep the complex functional. The interchange of catalytically active subunits that 
can be oxidatively damaged in large enzymatic complexes is a mechanism demonstrated 
in chloroplast Photosystem II 48-50 and in mammalian mitochondrial cI 51, where there 
seems to be an interchange of old damaged subunits for newly imported ones. If this 
model is correct, the turnover of UQCRFS1 should be faster than that of the other cIII2 
subunits, which is in fact the case in mouse tissues 52.  
To determine whether the rate of UQCRFS1 incorporation and turnover, as well as the 
N-terminal fragment clearance changes depending on the metabolic conditions would 
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be a question of great interest to understand the relevance of this process in the 
adaptation to different energetic demands. This could be tested in differentiated tissues, 
where mitochondria in general and cIII2 in particular could play a different metabolic 
role. It is also possible to analyze UQCRFS1 turnover in cultured cells grown in OXPHOS-
dependent (galactose as carbon source) and independent (glucose as carbon source) 
media. If this were to be changed, it would reflect how cIII2 maturation must adapt to an 
increased MRC activity.   
These questions can be experimentally addressed; their elucidation will contribute to 
clarify the complex regulatory mechanisms of OXPHOS and their implication in health 
and disease.   
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FIGURE LEGENDS 
 
 
 
Figure 1. UQCRFS1 pathway from synthesis of the precursor in the cytoplasm, transport 
into the mitochondrial matrix through the TOM/TIM23 import system, incorporation of 
the 2Fe-2S clusters in the matrix and translocation to pre-cIII2 in the inner membrane 
(IM). According to our model, the N-terminal MTS is cleaved off in situ by the 
UQCRC1+UQCRC2 MPP activity. See main text for more details.   
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Figure 2. Graphic alignment of the Rieske protein precursors from yeast (S. cerevisiae), 
fruit fly (D. melanogaster), chicken (G. gallus) and mammals (bovine, mouse and 
human). Numbers indicate relevant residue positions. The two yeast cleavage sites, at 
positions 22 and 30 are indicated with arrows. The main cleavage site, conserved in all 
organisms is indicated with the big arrow. Different color MTS indicates the lack of 
homology of these sequences, while the homology in the mature protein sequences in 
very high.  
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Figure 3. Structures of full complex III dimer (cIII2) and of isolated UQCRFS1 (of only 
one of the monomers), from bovine (PBD ID: 1BGY) and chicken (PBD ID: 3H1J). The 
arrows indicate the presence of the UQCRFS1 fragments in the cavity between UQCRC1 
and UQCRC2. Images were generated with MacPyMol 
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Table 1. UQCRFS1 MTS sequences found in the published cIII2 structures 
BOVINE STRUCTURES 
UQCRFS1 MTS: Positions 1 to 78 
PDB ID Reference UQCRFS1 positions found  
1BGY, 1BE3 (1) From 48 to 78 
1L0L, 1L0N, 1NTK, 
1NTM, 1NTZ, 1NU1, 
1SQB, 1SQP, 1SQQ, 
1SQV, 1SQX, 2FYU  
(53-56) From 1 to 57 
1PP9, 1PPJ, 2A06 (57) From 32 to 42 and from 48 to 78 
1QCR (58) From 21 to 48 
4D6U, 4D6T (59) 
Monomer 1: From 50 to 56 and from 
64 to 77 
Monomer 2: From 62 to 63 and from 
65 to 78 
5KLV (60) 
From 20 to 27; from 44 to 61 and 
from 63 to 70 
5NMI (61) From 49 to 78 
CHICKEN STRUCTURES 
UQCRFS1 MTS: Positions 1 to 76 
1BCC, 2BCC, 3BCC (3) ---- 
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3H1L, 3H1H, 3H1I,  
3H1J, 3H1K 
(62) From 45 to 63 
3CWB, 4U3F (63, 64) From 46 to 75 
3TGU (65) From 2 to 8 and from 46 to 75 
3L70, 3L71, 3L72, 
3L73, 3L74 
(66) From 45 to 75 
HUMAN STRUCTURE 
UQCRFS1 MTS: Positions 1 to 78 
5XTE (5) From 1 to 57 
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